8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Nov 4, 2025·SEC
Material company update
Oct 28, 2025·SEC
Nautilus Biotechnology, Inc.(NAUT)Earnings, Financials & Key Ratios
NAUT•NASDAQ
Price updated Jun 19, 2026
AboutNautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.Show more
- Revenue$0
- EBITDA-$60M+19.6%
- Net Income-$59M+16.6%
- EPS (Diluted)-0.47+16.1%
- ROE-32.27%-8.1%
NAUT Key Insights
Nautilus Biotechnology, Inc. (NAUT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 82 (top 18%)
✗Weaknesses
- ✗Profits declining 30.4% over 5 years
- ✗Weak Piotroski F-Score: 1/9
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when NAUT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NAUT Price & Volume
Nautilus Biotechnology, Inc. (NAUT) stock price & volume — 10-year historical chart
Loading chart...
NAUT Growth Metrics
Nautilus Biotechnology, Inc. (NAUT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM16.86%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM14.81%
Return on Capital
10 Years-30.67%
5 Years-25%
3 Years-28.81%
Last Year-31.96%
NAUT Recent Earnings
Nautilus Biotechnology, Inc. (NAUT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)
Q2 2026Latest
Apr 28, 2026Metric
Actual
Est
EPS
$0.12+17.2%
$0.14
Rev
—
$250,000
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.11+21.4%
$0.14
Rev
—
$1M
Q4 2025
Oct 27, 2025Metric
Actual
Est
EPS
$0.11+26.7%
$0.15
Rev
—
—
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$0.12+22.6%
$0.15
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.12vs $0.14+17.2% | —vs $250,000 |
| Q1 2026 | Feb 26, 2026 | $0.11vs $0.14+21.4% | —vs $1M |
| Q4 2025 | Oct 27, 2025 | $0.11vs $0.15+26.7% | — |
| Q3 2025 | Jul 31, 2025 | $0.12vs $0.15+22.6% | — |
Based on last 12 quarters of dataView full earnings history →
NAUT Peer Comparison
Nautilus Biotechnology, Inc. (NAUT) competitors in Diagnostics and Omics Tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CDNA | 1.35B | 26.18 | -65.45 | 13.79% | -1.98% | -2.61% | 0.06 | |
 SEER | 95.67M | 1.74 | -1.36 | 15.57% | -468.74% | -26.58% | 0.09 | |
 QBTS | 9.07B | 24.69 | -22.24 | 178.54% | -29.57% | -44.05% | 0.05 | |
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 | |
 PACB | 434.84M | 1.40 | -0.77 | 3.89% | -80.34% | -488.45% | 141.98 | |
 BFLY | 2.33B | 8.90 | -28.71 | 18.96% | -73.63% | -36.79% | 0.10 | |
 TWST | 5.45B | 87.56 | -67.35 | 20.32% | -19.85% | -17.46% | 0.29 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 |
Compare NAUT vs Peers
Nautilus Biotechnology, Inc. (NAUT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NAUT Income Statement
Nautilus Biotechnology, Inc. (NAUT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 2.35M | 2.84M | 3.42M | 5.71M | 6.35M | 6.46M | 6.32M |
COGS % of Revenue | - | - | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | -2.35M▲ 0% | -2.84M▼ 21.1% | -3.42M▼ 20.2% | -5.71M▼ 67.0% | -6.35M▼ 11.4% | -6.46M▼ 1.8% | -6.32M▲ 0% |
Gross Margin % | - | - | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | -21.14% | -20.2% | -67.01% | -11.36% | -1.76% | - |
Operating Expenses | 111.68M | 10.11M | 13.4M | 47.66M | 60.2M | 70.45M | 75.12M | 60.37M | 59.28M |
OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
Selling, General & Admin | 111.68M | 1.62M | 3.31M | 21.15M | 23.75M | 28.9M | 31M | 25.73M | 22.47M |
SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
Research & Development | 0 | 8.49M | 10.09M | 26.51M | 36.45M | 47.25M | 50.48M | 41.11M | 39.75M |
R&D % of Revenue | - | - | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | -5.71M | -6.35M | -6.46M | -1000K |
Operating Income | -111.68M▲ 0% | -10.11M▲ 90.9% | -15.74M▼ 55.7% | -50.5M▼ 220.7% | -63.62M▼ 26.0% | -76.15M▼ 19.7% | -81.48M▼ 7.0% | -66.84M▲ 18.0% | -64.12M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - | - | - |
Operating Income Growth % | - | 90.95% | -55.73% | -220.74% | -25.98% | -19.7% | -6.99% | 17.97% | - |
EBITDA | 626.6M | -9.56M | -13.4M | -47.66M | -60.2M | -74.3M | -75.12M | -60.37M | -57.8M |
EBITDA Margin % | - | - | - | - | - | - | - | - | - |
EBITDA Growth % | - | -101.53% | -40.12% | -255.69% | -26.33% | -23.42% | -1.1% | 19.64% | 14.4% |
D&A (Non-Cash Add-back) | 738.28M | 548K | 2.35M | 2.84M | 3.42M | 1.85M | 6.35M | 6.46M | 6.32M |
EBIT | -111.68M | -10.11M | -15.62M | -50.31M | -57.92M | -76.15M | -70.78M | -59M | -58.51M |
Net Interest Income | 0 | 0 | 0 | 329K | 0 | 12.55M | 10.78M | 7.87M | 7.08M |
Interest Income | 0 | 0 | 0 | 329K | 5.82M | 12.55M | 10.78M | 7.87M | 7.08M |
Interest Expense | 0 | 0 | 0 | 0 | 5.82M | 0 | 0 | 0 | 0 |
Other Income/Expense | 738.28M | 492K | 125K | 183K | 5.69M | 12.48M | 10.7M | 7.84M | 7.03M |
Pretax Income | 626.6M▲ 0% | -9.62M▼ 101.5% | -15.62M▼ 62.4% | -50.31M▼ 222.1% | -57.92M▼ 15.1% | -63.67M▼ 9.9% | -70.78M▼ 11.2% | -59M▲ 16.6% | -57.09M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | 626.6M▲ 0% | -9.62M▼ 101.5% | -15.62M▼ 62.4% | -50.31M▼ 222.1% | -57.92M▼ 15.1% | -63.67M▼ 9.9% | -70.78M▼ 11.2% | -59M▲ 16.6% | -57.09M▲ 0% |
Net Margin % | - | - | - | - | - | - | - | - | - |
Net Income Growth % | - | -101.53% | -62.39% | -222.14% | -15.12% | -9.93% | -11.16% | 16.64% | 16.86% |
Net Income (Continuing) | 626.6M | -9.62M | -15.62M | -50.31M | -57.92M | -63.67M | -70.78M | -59M | -57.09M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 87.18▲ 0% | -1.59▼ 101.8% | -0.47▲ 70.4% | -0.60▼ 27.7% | -0.46▲ 23.3% | -0.51▼ 10.9% | -0.56▼ 9.8% | -0.47▲ 16.1% | -0.45▲ 0% |
EPS Growth % | - | -101.82% | 70.44% | -27.66% | 23.33% | -10.87% | -9.8% | 16.07% | 14.81% |
EPS (Basic) | 87.18 | -1.59 | -0.47 | -0.60 | -0.46 | -0.51 | -0.56 | -0.47 | - |
Diluted Shares Outstanding | 7.19M | 6.07M | 33.07M | 84.46M | 124.59M | 124.92M | 125.43M | 126.26M | 126.63M |
Basic Shares Outstanding | 7.19M | 6.07M | 33.07M | 84.46M | 124.59M | 124.92M | 125.43M | 126.26M | 126.63M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
NAUT Balance Sheet
Nautilus Biotechnology, Inc. (NAUT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.33M | 16.96M | 77.66M | 349.22M | 187.21M | 176.84M | 132.83M | 105.96M | 98.83M |
Cash & Short-Term Investments | 144.49B | 16.66M | 76.74M | 345.73M | 184.47M | 173.42M | 129.89M | 103.41M | 95.87M |
Cash Only | 1.2M | 595K | 36.61M | 185.62M | 114.52M | 19.4M | 27.65M | 12.39M | 14.63M |
Short-Term Investments | 144.49B | 16.06M | 40.13M | 160.11M | 69.95M | 154.02M | 102.25M | 91.02M | 81.24M |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
Other Current Assets | -144.49B | 0 | 0 | 0 | 0 | 3.42M | 2.93M | 2.56M | 2.96M |
Total Non-Current Assets | 144.49M | 1.58M | 7.35M | 49.23M | 162.84M | 128.73M | 109.92M | 85.15M | 78.95M |
Property, Plant & Equipment | 0 | 1.12M | 6.21M | 31.86M | 32.57M | 36.9M | 32.33M | 31.23M | 30.27M |
Fixed Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 144.49M | 0 | 0 | 16.37M | 129.17M | 90.65M | 76.41M | 52.74M | 168.94M |
Other Non-Current Assets | 0 | 459K | 1.14M | 997K | 1.11M | 1.18M | 1.18M | 1.18M | 1.18M |
Total Assets | 145.82M▲ 0% | 18.54M▼ 87.3% | 85.01M▲ 358.5% | 398.45M▲ 368.7% | 350.05M▼ 12.1% | 305.56M▼ 12.7% | 242.74M▼ 20.6% | 191.11M▼ 21.3% | 177.78M▲ 0% |
Asset Turnover | - | - | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | -87.28% | 358.48% | 368.7% | -12.15% | -12.71% | -20.56% | -21.27% | -87.66% |
Total Current Liabilities | 5K | 490K | 3.02M | 5.81M | 6.79M | 9.12M | 7.63M | 7.95M | 8.34M |
Accounts Payable | 0 | 289K | 470K | 1.72M | 1.27M | 1.64M | 987K | 943K | 1.19M |
Days Payables Outstanding | - | - | 73.12 | 221.29 | 135.91 | 104.86 | 56.71 | 53.24 | 57.73 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3.83M | 3.85M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 5K | 77K | 617K | 388K | 438K | 2.97M | 2.55M | 3.18M | 3.31M |
Current Ratio | 266.45x | 34.62x | 25.73x | 60.09x | 27.57x | 19.39x | 17.40x | 13.33x | 11.85x |
Quick Ratio | 266.45x | 34.62x | 25.73x | 60.09x | 27.57x | 19.39x | 17.40x | 13.33x | 11.85x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 5M | 275M | 111.71M | 29.06M | 28.34M | 31.09M | 26.38M | 26.19M | 25.02M |
Long-Term Debt | 5M | 275M | 0 | 0 | 0 | 0 | 0 | 26.19M | 25.02M |
Capital Lease Obligations | 0 | 0 | 3.3M | 29.06M | 28.34M | 31.09M | 26.38M | 0 | 46.75M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 108.42M | 0 | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 140.82M | 490K | 114.73M | 34.87M | 35.13M | 40.21M | 34.01M | 34.14M | 33.36M |
Total Debt | 5M | 275M | 4.78M | 30.03M | 30.33M | 34.63M | 30.48M | 30.02M | 28.87M |
Net Debt | 3.8M | 274.4M | -31.83M | -155.59M | -84.19M | 15.23M | 2.83M | 17.63M | 14.25M |
Debt / Equity | 1.00x | 15.23x | - | 0.08x | 0.10x | 0.13x | 0.15x | 0.19x | 0.20x |
Debt / EBITDA | 0.01x | - | - | - | - | - | - | - | -0.50x |
Net Debt / EBITDA | 0.01x | - | - | - | - | - | - | - | -0.25x |
Interest Coverage | - | - | - | - | -9.96x | - | - | - | - |
Total Equity | 5M▲ 0% | 18.05M▲ 261.0% | -29.72M▼ 264.6% | 363.58M▲ 1323.3% | 314.92M▼ 13.4% | 265.35M▼ 15.7% | 208.73M▼ 21.3% | 156.97M▼ 24.8% | 144.41M▲ 0% |
Equity Growth % | - | 261.04% | -264.64% | 1323.3% | -13.38% | -15.74% | -21.34% | -24.8% | -97.85% |
Book Value per Share | 0.70 | 2.98 | -0.90 | 4.30 | 2.53 | 2.12 | 1.66 | 1.24 | 1.14 |
Total Shareholders' Equity | 5M | 18.05M | -29.72M | 363.58M | 314.92M | 265.35M | 208.73M | 156.97M | 144.41M |
Common Stock | 0 | 1K | 1K | 12K | 12K | 13K | 13K | 13K | 13K |
Retained Earnings | 626.6K | -14.71M | -30.32M | -80.64M | -138.56M | -202.24M | -273.02M | -332.02M | -346.72M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 7K | 3K | -184K | -1.85M | -255K | 57K | 243K | -91K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NAUT Cash Flow Statement
Nautilus Biotechnology, Inc. (NAUT) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -238.3M | -9.66M | -14M | -39.24M | -45.81M | -51.71M | -59.15M | -50.7M | -49.86M |
Operating CF Margin % | - | - | - | - | - | - | - | - | - |
Operating CF Growth % | - | 95.95% | -44.86% | -180.37% | -16.73% | -12.89% | -14.38% | 14.29% | 49.01% |
Net Income | 626.6M | -9.62M | -15.62M | -50.31M | -57.92M | -63.67M | -70.78M | -59M | -57.09M |
Depreciation & Amortization | 0 | 548K | 2.35M | 2.84M | 3.42M | 5.71M | 6.35M | 6.46M | 6.32M |
Stock-Based Compensation | 0 | 110K | 369K | 7.93M | 10.38M | 12.14M | 12.7M | 6.84M | 6.04M |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -866.23M | -157K | 295K | 320K | -890K | -2.66M | -1.96M | -1.42M | -947K |
Working Capital Changes | 1.33M | -545K | -1.39M | -22K | -788K | -3.22M | -5.46M | -3.58M | -4.18M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 123K | 1.26M | -561K | 393K | -578K | -69K | 262K |
Cash from Investing | 1.2M | 4.05M | -25.28M | -138.96M | -25.74M | -43.73M | 66.25M | 35.22M | 29.95M |
Capital Expenditures | 0 | -926K | -921K | -2.27M | -2.32M | -2.44M | -2.12M | -1.28M | -1.57M |
CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 1.2M | 4.98M | 0 | 0 | 0 | 0 | 154.65M | 0 | -11.13M |
Cash from Financing | 145.19B | 36K | 75.9M | 327.45M | 562K | 368K | 1.14M | 214K | 1.3M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 0 | 75.86M | -7.96M | 562K | 368K | 1.14M | 214K | 1.3M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | -1.2M | -874.33K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 145.19B | 36K | 42K | 335.41M | 0 | 0 | 0 | 0 | 0 |
Net Change in Cash | 1.2M▲ 0% | 595K▼ 50.3% | 36.62M▲ 6055.3% | 149.24M▲ 307.5% | -70.98M▼ 147.6% | -95.08M▼ 33.9% | 8.25M▲ 108.7% | -15.26M▼ 285.0% | -18.61M▲ 0% |
Free Cash Flow | -238.3M▲ 0% | -10.59M▲ 95.6% | -14.92M▼ 40.9% | -41.51M▼ 178.3% | -48.13M▼ 15.9% | -54.15M▼ 12.5% | -61.27M▼ 13.1% | -51.97M▲ 15.2% | -51.43M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - | - | - |
FCF Growth % | - | 95.56% | -40.89% | -178.27% | -15.95% | -12.51% | -13.14% | 15.17% | 12.11% |
FCF per Share | -33.15 | -1.75 | -0.45 | -0.49 | -0.39 | -0.43 | -0.49 | -0.41 | -0.41 |
FCF Conversion (FCF/Net Income) | -0.38x | 1.00x | 0.90x | 0.78x | 0.79x | 0.81x | 0.84x | 0.86x | 0.90x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
NAUT Key Ratios
Nautilus Biotechnology, Inc. (NAUT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -83.45% | - | -30.14% | -17.07% | -21.95% | -29.86% | -32.27% | -35.04% |
Return on Invested Capital (ROIC) | -5.03% | -10.23% | -51.73% | -21.75% | -22.34% | -24.83% | -25.96% | -28.27% |
Debt / Equity | 15.23x | - | 0.08x | 0.10x | 0.13x | 0.15x | 0.19x | 0.20x |
Interest Coverage | - | - | - | -9.96x | - | - | - | - |
FCF Conversion | 1.00x | 0.90x | 0.78x | 0.79x | 0.81x | 0.84x | 0.86x | 0.90x |
Related:NAUT Dividend History·NAUT Revenue History·NAUT Price History·NAUT P/E History·NAUT Financial Ratios·NAUT Institutional Holders
NAUT SEC Filings & Documents
Nautilus Biotechnology, Inc. (NAUT) SEC filings — annual & quarterly reports (10-K, 10-Q)
NAUT Frequently Asked Questions
Nautilus Biotechnology, Inc. (NAUT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Nautilus Biotechnology, Inc. (NAUT) grew revenue by 0.0% over the past year. Growth has been modest.
Nautilus Biotechnology, Inc. (NAUT) reported a net loss of $57.1M for fiscal year 2025.
Dividend & Returns
Nautilus Biotechnology, Inc. (NAUT) has a return on equity (ROE) of -32.3%. Negative ROE indicates the company is unprofitable.
Nautilus Biotechnology, Inc. (NAUT) had negative free cash flow of $51.4M in fiscal year 2025, likely due to heavy capital investments.